Alpelisib, a PI3K inhibitor, is approved for patients with HR+, HER2- and PIK3CA-mutated cancers in combination with fulvestrant [6], while the PARP inhibitor olaparib targets BRCA mutations in early breast cancer [7]. This evidence concerns the gene HR and breast carcinoma.